Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 13, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Laying the Foundation for Clinically Actionable Genomic Subtyping in Diffuse Large B-cell Lymphoma.

Margaret A Shipp1, Louis M Staudt2, Daniel J Hodson3

  • 1Dana-Farber Cancer Institute , Boston, Massachusetts.

Blood Cancer Discovery
|May 12, 2026
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracellular iron homeostasis-regulated epigenetic reprogramming contributes to -7/del(7q) leukemia.

Nature communications·2026
Same author

EpiATLAS - a reference for human epigenomic research.

bioRxiv : the preprint server for biology·2026
Same author

Harmonizing standards and resources for the medical genome.

Nature·2026
Same author

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

CA: a cancer journal for clinicians·2026
Same author

LncRNA IRENA promotes peripheral T-cell lymphoma progression through scaffolding ARHGEF1 and FMNL1 to modulate RHOA GTPase/MAPK signaling.

Oncogene·2026
Same authorSame journal

A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma.

Blood cancer discovery·2026

Stratifying diffuse large B-cell lymphoma (DLBCL) remains challenging. This review synthesizes expert opinions and clinical trial data to guide the development of precise DLBCL subtyping for better treatment strategies.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) exhibits significant clinical and genetic heterogeneity.
  • Genetically defined subtypes of DLBCL have therapeutic implications, but clear classification boundaries and data integration remain challenging.
  • The lack of a universally accepted stratification method hinders the implementation of precision medicine in DLBCL.

Purpose of the Study:

  • To review expert perspectives on DLBCL classification.
  • To outline practical workflows for DLBCL subtyping.
  • To distill lessons from clinical trials for developing clinically relevant DLBCL subtyping approaches.

Main Methods:

  • Juxtaposition of expert viewpoints on DLBCL classification.
  • Analysis of practical workflow considerations for subtyping.

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

Related Experiment Videos

Last Updated: May 13, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

  • Distillation of lessons learned from clinical trials.
  • Synthesis of experimental design and analytic considerations.

    • Main Results:

    • Expert consensus is emerging on the importance of genetic subtyping in DLBCL.
    • Practical workflows are being developed to integrate diverse molecular data.
    • Clinical trial data highlight the need for robust and reproducible subtyping methods.
    • Challenges remain in defining discrete classes and handling unclassifiable cases.

    Conclusions:

    • A unified approach to DLBCL stratification is crucial for advancing precision medicine.
    • Integrating genetic and clinical data is key to refining DLBCL classification.
    • Further research and standardization are needed to overcome current barriers in DLBCL subtyping.